PHILADELPHIA, Jan. 14 /PRNewswire/ -- Kibow Biotech, Inc. is pleased to announce that it has been granted an International Patent Cooperation Treaty (PCT) patent from Australia, China and India. The approved patent, "Prebiotic and Probiotic Compositions and their Method of use for Gut-based Therapy," protects the composition and method behind the Company's oral probiotic product formulation (Kibow Biotics(R)) which may significantly reduce concentrations of several nitrogenous waste metabolites that accumulate in renal deficiency. The serial numbers for this patent are: 20022342641 (Australia), ZL 02810078.6 (China) and 1029/MUMNP/2003, 205478 (India). Kibow Biotech has an identical PCT patent pending in Canada, the European Union, Japan, and South Korea.
In addition, the term "Enteric Dialysis(TM)" has been recognized as a registered service trademark by the patent and trademark authority of the Government of India. "Enteric Dialysis(TM)" designates the technology behind the Company's proprietary probiotic product formulation which has the ability to eliminate uremic nitrogenous waste metabolites via the gut route.
Kibow Biotech has another PCT application, "Compositions and Methods for Augmenting Kidney Function," under national review in all of the aforementioned countries except Australia where this patent has also been approved (#2002255717).
Dr. Natarajan Ranganathan, VP (R&D) and interim CEO, stated, "In addition to our PCT patents, Kibow has already obtained three US patents, with four more additional patents under examination process. The rapidly expanding intellectual property portfolio for our unique 'Enteric Dialysis(TM)' platform technology has added immense potential to our company products for kidney failure applications worldwide."
About Kibow Clinical Trials
Currently Kibow has begun pilot-scale human clinical studies of its uremic formulation (Kibow Biotics(R)) in six different sites and five countries. his is a short-term (six-month) double-blind, placebo-controlled, cross-over study mainly designed to establish the safety (US FDA's Generally Recognized as Safe ("GRAS") status) and pre-market notification of its intended uremic syndrome applications. In addition, this clinical trial is evaluating the possible use of Kibow Biotics(R) as a dietary or nutritional supplement for chronic kidney failure (stage III and IV) predialysis patients worldwide.
For more information, visit http://www.kibowbiotech.com
This press release contains forward-looking statements that reflect
management's current views of future events, including the status of
development of the dietary supplement formulation, Kibow Biotics(R), for
kidney failure applications, and the possible benefits of Kibow Biotics in
slowing the progression of chronic kidney failure or helping patients feel
better. Kibow is not a pharmaceutical company. Kibow products are not drugs
and may not be considered as a treatment or a therapy. The dietary
supplement formulation of Kibow Biotics will not cure, prevent or mitigate
any disease. Actual results may differ significantly from the above
forward-looking statements due to a number of factors including but not
limited to the possibility that Kibow Biotics(R) may not prove to be safe
or show evidence of clinical activity in the current limited human trials
or that data from patients enrolled in the study may not be useful or
conclusive or sufficient to guide future development of Kibow Biotics(R).
Other factors that could cause or contribute to differences in actual
results include, but are not limited to, whether or not the Company or any
of its collaborators will be able to develop dietary supplements using the
technologies of the Company; risks associated with completing clinical
trials of product candidates; the possibility that clinical testing may
reveal to be undesirable and unintended side effects or other
characteristics that may prevent or limit the commercial use of proposed
products; whether the cash resources of the Company will be sufficient to
fund operations as planned; reliance on key employees, especially senior
management; the uncertainty of the Company's future access to capital; the
risk that the Company may not secure or maintain relationships with
collaborators; and the Company's dependence on intellectual property. The
Company expressly disclaims any intent or obligation to update these
forward- looking statements except as required by law.
Dr. Natarajan Ranganathan
CEO and VP Research and Development
Tel: 1 (610) 353 5130
Web site: http://www.kibowbiotech.com
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
|SOURCE Kibow Biotech, Inc.|
Copyright©2008 PR Newswire.
All rights reserved